Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024
Theravance Biopharma (NASDAQ: TBPH) has scheduled its third quarter 2024 financial results announcement and business update for November 12, 2024, after market close. The company will host a conference call and simultaneous webcast at 5:00 pm EST on the same day. Interested participants can pre-register for the telephone conference, while those preferring to listen via the internet can access the webcast through Theravance's website. A replay will be available online for 30 days until December 12, 2024.
Theravance Biopharma (NASDAQ: TBPH) ha programmato l'annuncio dei risultati finanziari del terzo trimestre 2024 e un aggiornamento aziendale per il 12 novembre 2024, dopo la chiusura del mercato. L'azienda ospiterà una conferenza telefonica e una diretta web simultanea alle 17:00 EST nello stesso giorno. I partecipanti interessati possono registrarsi in anticipo per la conferenza telefonica, mentre coloro che preferiscono ascoltare via internet possono accedere alla diretta sul sito web di Theravance. Una registrazione sarà disponibile online per 30 giorni fino al 12 dicembre 2024.
Theravance Biopharma (NASDAQ: TBPH) ha programado el anuncio de sus resultados financieros del tercer trimestre de 2024 y una actualización empresarial para el 12 de noviembre de 2024, después del cierre del mercado. La empresa organizará una llamada de conferencia y una transmisión web simultánea a las 5:00 pm EST el mismo día. Los participantes interesados pueden preinscribirse para la conferencia telefónica, mientras que aquellos que prefieren escuchar a través de internet pueden acceder a la transmisión web a través del sitio web de Theravance. Una grabación estará disponible en línea durante 30 días hasta el 12 de diciembre de 2024.
Theravance Biopharma (NASDAQ: TBPH)는 2024년 3분기 재무 결과 발표 및 비즈니스 업데이트를 2024년 11월 12일 시장 마감 후에 진행할 예정입니다. 회사는 동일한 날 오후 5시 EST에 전화 회의와 동시에 웹 캐스트를 개최합니다. 관심 있는 참가자는 전화 회의에 사전 등록할 수 있으며, 인터넷을 통해 듣기를 원하는 분은 Theravance의 웹사이트를 통해 웹 캐스트에 접근할 수 있습니다. 재생은 2024년 12월 12일까지 30일 동안 온라인에서 제공됩니다.
Theravance Biopharma (NASDAQ: TBPH) a programmé l'annonce de ses résultats financiers pour le troisième trimestre 2024 et une mise à jour de l'entreprise pour le 12 novembre 2024, après la clôture du marché. L'entreprise organisera une conférence téléphonique et un webinaire simultané à 17h00 EST le même jour. Les participants intéressés peuvent s'inscrire à l'avance pour la conférence téléphonique, tandis que ceux qui préfèrent écouter via Internet peuvent accéder au webinaire via le site web de Theravance. Un enregistrement sera disponible en ligne pendant 30 jours jusqu'au 12 décembre 2024.
Theravance Biopharma (NASDAQ: TBPH) hat die Bekanntgabe seiner finanziellen Ergebnisse für das dritte Quartal 2024 und ein Geschäftsupdate für den 12. November 2024, nach Marktschluss, geplant. Das Unternehmen wird am selben Tag um 17:00 Uhr EST eine Telefonkonferenz und eine gleichzeitige Webcast veranstalten. Interessierte Teilnehmer können sich im Voraus für die Telefonkonferenz registrieren, während diejenigen, die lieber über das Internet zuhören möchten, über die Website von Theravance auf den Webcast zugreifen können. Eine Aufzeichnung wird 30 Tage lang bis zum 12. Dezember 2024 online verfügbar sein.
- None.
- None.
Conference Call Information
To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.com, under the Investors section, Events and Presentations.
A replay of the webcast will be available on Theravance Biopharma's website for 30 days through December 12, 2024.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the
YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.
Contact:
investor.relations@theravance.com
650-808-4045
View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-report-third-quarter-2024-financial-results-on-november-12-2024-302285433.html
SOURCE Theravance Biopharma, Inc.
FAQ
When will Theravance Biopharma (TBPH) report Q3 2024 earnings?
What time is Theravance Biopharma's (TBPH) Q3 2024 earnings call?
How long will Theravance Biopharma's (TBPH) Q3 2024 earnings call replay be available?
